169 related articles for article (PubMed ID: 31150417)
21. Targeting a family B GPCR/RAMP receptor complex: CGRP receptor antagonists and migraine.
Moore EL; Salvatore CA
Br J Pharmacol; 2012 May; 166(1):66-78. PubMed ID: 21871019
[TBL] [Abstract][Full Text] [Related]
22. Adrenomedullin - Current perspective on a peptide hormone with significant therapeutic potential.
Fischer JP; Els-Heindl S; Beck-Sickinger AG
Peptides; 2020 Sep; 131():170347. PubMed ID: 32569606
[TBL] [Abstract][Full Text] [Related]
23. Development of chimeric and bifunctional antagonists for CLR/RAMP receptors.
Chang CL; Hsu SYT
PLoS One; 2019; 14(5):e0216996. PubMed ID: 31150417
[TBL] [Abstract][Full Text] [Related]
24. Probing the Mechanism of Receptor Activity-Modifying Protein Modulation of GPCR Ligand Selectivity through Rational Design of Potent Adrenomedullin and Calcitonin Gene-Related Peptide Antagonists.
Booe JM; Warner ML; Roehrkasse AM; Hay DL; Pioszak AA
Mol Pharmacol; 2018 Apr; 93(4):355-367. PubMed ID: 29363552
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular effects of exogenous adrenomedullin and CGRP in Ramp and Calcrl deficient mice.
Pawlak JB; Wetzel-Strong SE; Dunn MK; Caron KM
Peptides; 2017 Feb; 88():1-7. PubMed ID: 27940069
[TBL] [Abstract][Full Text] [Related]
26. Receptor activity-modifying protein-dependent effects of mutations in the calcitonin receptor-like receptor: implications for adrenomedullin and calcitonin gene-related peptide pharmacology.
Watkins HA; Walker CS; Ly KN; Bailey RJ; Barwell J; Poyner DR; Hay DL
Br J Pharmacol; 2014 Feb; 171(3):772-88. PubMed ID: 24199627
[TBL] [Abstract][Full Text] [Related]
27. Calcitonin and Amylin Receptor Peptide Interaction Mechanisms: INSIGHTS INTO PEPTIDE-BINDING MODES AND ALLOSTERIC MODULATION OF THE CALCITONIN RECEPTOR BY RECEPTOR ACTIVITY-MODIFYING PROTEINS.
Lee SM; Hay DL; Pioszak AA
J Biol Chem; 2016 Apr; 291(16):8686-700. PubMed ID: 26895962
[TBL] [Abstract][Full Text] [Related]
28. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
Tepper SJ
Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
[TBL] [Abstract][Full Text] [Related]
29. CGRP blockade by galcanezumab was not associated with reductions in signs and symptoms of knee osteoarthritis in a randomized clinical trial.
Jin Y; Smith C; Monteith D; Brown R; Camporeale A; McNearney TA; Deeg MA; Raddad E; Xiao N; de la Peña A; Kivitz AJ; Schnitzer TJ
Osteoarthritis Cartilage; 2018 Dec; 26(12):1609-1618. PubMed ID: 30240937
[TBL] [Abstract][Full Text] [Related]
30. Cryo-EM structure of the active, G
Liang YL; Khoshouei M; Deganutti G; Glukhova A; Koole C; Peat TS; Radjainia M; Plitzko JM; Baumeister W; Miller LJ; Hay DL; Christopoulos A; Reynolds CA; Wootten D; Sexton PM
Nature; 2018 Sep; 561(7724):492-497. PubMed ID: 30209400
[TBL] [Abstract][Full Text] [Related]
31. Regulation of calcitonin gene-related peptide expression through the COX-2/mPGES-1/PGE2 pathway in the infrapatellar fat pad in knee osteoarthritis.
Aikawa J; Uchida K; Takano S; Inoue G; Iwase D; Miyagi M; Mukai M; Shoji S; Sekiguchi H; Takaso M
Lipids Health Dis; 2018 Sep; 17(1):215. PubMed ID: 30205824
[TBL] [Abstract][Full Text] [Related]
32. Structure-function analyses reveal a triple β-turn receptor-bound conformation of adrenomedullin 2/intermedin and enable peptide antagonist design.
Roehrkasse AM; Booe JM; Lee SM; Warner ML; Pioszak AA
J Biol Chem; 2018 Oct; 293(41):15840-15854. PubMed ID: 30139742
[TBL] [Abstract][Full Text] [Related]
33. Pharmaceutical Approval Update.
Choy M
P T; 2018 Aug; 43(8):461-462. PubMed ID: 30100686
[TBL] [Abstract][Full Text] [Related]
34. Solid-Phase Thiol-Ene Lipidation of Peptides for the Synthesis of a Potent CGRP Receptor Antagonist.
Williams ET; Harris PWR; Jamaluddin MA; Loomes KM; Hay DL; Brimble MA
Angew Chem Int Ed Engl; 2018 Sep; 57(36):11640-11643. PubMed ID: 29978532
[TBL] [Abstract][Full Text] [Related]
35. Molecular studies of CGRP and the CGRP family of peptides in the central nervous system.
Hendrikse ER; Bower RL; Hay DL; Walker CS
Cephalalgia; 2019 Mar; 39(3):403-419. PubMed ID: 29566540
[TBL] [Abstract][Full Text] [Related]
36. Phase I Trial of the Combination of Docetaxel, Prednisone, and Pasireotide in Metastatic Castrate-Resistant Prostate Cancer.
Thakur MK; Heilbrun L; Dobson K; Boerner J; Stark K; Li J; Smith D; Heath E; Fontana J; Vaishampayan U
Clin Genitourin Cancer; 2018 Jun; 16(3):e695-e703. PubMed ID: 29534939
[TBL] [Abstract][Full Text] [Related]
37. Intermedin Enlarges the Vascular Lumen by Inducing the Quiescent Endothelial Cell Proliferation.
Wang LJ; Xiao F; Kong LM; Wang DN; Li HY; Wei YG; Tan C; Zhao H; Zhang T; Cao GQ; Zhang K; Wei YQ; Yang HS; Zhang W
Arterioscler Thromb Vasc Biol; 2018 Feb; 38(2):398-413. PubMed ID: 29242270
[TBL] [Abstract][Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
